Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – As AI reshapes the future of medicine, understanding how patients actually feel about it is becoming just as critical as the tech itself. According to a new study published in Nature, researchers developed an “AI Affinity Score” to predict how much artificial intelligence a patient is comfortable with in their healthcare experience. The findings revealed that education level and region significantly influence patient attitudes, and that the model can accurately help personalize AI integration to improve care quality and patient satisfaction. That kind of insight isn’t just academic—it’s reshaping how investors spot the next wave of innovation in healthcare. With the global AI healthcare market expected to surpass $110 billion by 2030, companies like Avant Technologies, Inc. (OTCQB: AVAI), Amesite Inc. (NASDAQ: AMST), Claritev Corporation (NYSE: CTEV), Compugen Ltd. (NASDAQ: CGEN), and SoundHound AI, Inc. (NASDAQ: SOUN) are drawing fresh attention from the market.
And the upside doesn’t stop there—Accenture projects AI could inject an additional $461 billion into the healthcare sector by 2035, as it races past the $2.26 trillion mark. This shift isn’t just about diagnostics or robotics—it’s about rewiring the entire healthcare ecosystem from the inside out, and multiple companies are positioning themselves to capitalize on the shift.
Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have officially launched a transformative new preventative care model aimed at chronic disease patients across Latin America—reshaping how and where care is delivered.
At the center of this rollout is a seamless, pharmacy-based experience that allows diabetic patients to receive free retinal risk screenings at local pharmacy chains. The goal is to eliminate access barriers to early diagnosis by removing the need for specialist visits. The companies are working closely with pharmacies, clinics, insurers, and pharma partners to align incentives and activate earlier interventions. A growing referral network now routes “at risk” patients—identified by Ainnova’s AI platform—to medical specialists for follow-up care.
It’s a strategic and scalable approach to one of the biggest gaps in modern healthcare: detecting chronic conditions like diabetic retinopathy before symptoms appear. Avant and Ainnova are now proving that preventive care can be both frictionless for the patient and financially sustainable across the healthcare ecosystem.
With multiple commercial agreements and pilots already underway, the companies are forecasting a rapid expansion in reach and revenue heading into 2026. This growth is especially significant for Avant, which co-founded Ai-Nova Acquisition Corp. (AAC) to commercialize Ainnova’s technology portfolio and holds worldwide licensing rights—including across Latin America, where this model is being rolled out.
The milestone announcement comes just one day after a key regulatory development: on July 7, the JV team held its scheduled pre-submission meeting with the U.S. FDA. This session was set up to help determine the pathway for 510(k) clearance for Vision AI, the companies’ flagship diagnostic platform for diabetic retinopathy and other retinal diseases.
“We’re approaching a key milestone,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-Nova Acquisition Corp. “We’ve been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we’re optimistic about the outcome. Diabetic retinopathy is the number one cause of preventable blindness worldwide. That’s unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer’s, cardiovascular disease, and more.”
Avant’s broader diabetes strategy continues to evolve. In addition to the pharmacy-based rollout and FDA clearance push, the company is preparing to launch a new standalone venture to pursue a potential therapeutic candidate for diabetes. This move would integrate leadership, data, and IP under a single operating company—eliminating holding-company inefficiencies and aligning structure with strategic execution.
Over 30% of people living with diabetes will develop diabetic retinopathy—a condition that’s treatable when caught early but remains a leading cause of vision loss globally. Vision AI is designed to change that, using retinal imaging and artificial intelligence to deliver low-cost, accurate screenings without the need for on-site specialists. The system is currently being piloted inside Grupo Dökka’s pharmacy chains—Fischel and La Bomba—with free scans available to the public.
In parallel, the team is finalizing a next-generation, cloud-connected retinal camera optimized for use in clinics and rural areas. Future disease modules are also in development, including a dementia screening tool powered by blood biomarker integration.
“We’re committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world,” added Vargas. “That’s the mission behind everything we do.”
A previously announced non-binding LOI remains in place for Avant to acquire 100% of Ainnova Tech—a move that would simplify the joint venture structure and bring all commercialization rights, IP, and leadership under one public umbrella.
Ainnova’s model is designed to unify the entire chronic care ecosystem. Key stakeholders—including pharmacies, clinics, insurance providers, and pharmaceutical partners—are now aligned around a single, scalable workflow. Patients flagged as “at-risk” by the AI platform are referred to specialists for timely treatment, enabling earlier intervention and better outcomes at lower cost.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Amesite Inc. (NASDAQ: AMST) has expanded its flagship NurseMagic™ platform to support 16 languages, directly addressing the needs of nearly 1 million U.S. nurses who speak English as a second language.
“This rollout reflects our disciplined approach to targeting segments with clear, documented needs — including the nearly one in five nurses in the U.S. who speak English as a second language,” said Madison Bush, Director of Corporate Operations for Amesite. “By addressing the needs of this workforce, who must document in English, we’re positioned to capture value domestically and expand internationally.”
The AI-powered, HIPAA-compliant charting app now enables faster and more confident documentation across multilingual healthcare environments. The update strengthens Amesite’s growing B2B and B2C traction, especially as it recently reported a 2.4× quarter-over-quarter revenue increase.
Claritev Corporation (NYSE: CTEV) has joined the Coalition for Health AI (CHAI), aligning itself with leading health systems, researchers, and technology firms working to promote responsible AI in healthcare.
"Joining CHAI is a natural extension of our mission to improve healthcare affordability and transparency through responsible, data-driven innovation," said Fernando Schwartz, Ph.D., Chief Artificial Intelligence Officer of Claritev. "We are proud to be part of a coalition that shares our values and is actively shaping the future of health AI in a way that delivers meaningful impact for patients, providers, and payors alike."
The company plans to contribute its deep expertise in healthcare data integration to help shape industry frameworks focused on fairness, transparency, and patient safety. The move supports Claritev’s broader mission to make healthcare more affordable and data-driven across its network of over 700 payors and 1.4 million providers.
Back in June, Compugen Ltd. (NASDAQ: CGEN) showcased its AI- and machine learning–based research at the EACR Congress in Lisbon, focusing on immune evasion and resistance mechanisms in triple-negative breast cancer (TNBC).
The team presented models capable of predicting TNBC subtypes using integrative single-cell data, offering insights into how tumors bypass immunotherapy. These findings further validate Compugen’s approach to target discovery through computational biology. As a clinical-stage company with multiple partnered and proprietary programs, Compugen continues to bridge AI insights with therapeutic development.
SoundHound AI, Inc. (NASDAQ: SOUN) has partnered with Allina Health to launch “Alli,” a voice-enabled AI agent that integrates directly with electronic medical records to streamline patient interactions.
"Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance."
Since launch, the HIPAA-compliant system has improved call times and reduced hold delays, with 80% of calls answered in under 45 seconds. By offloading routine tasks, Allina’s staff can now focus more on complex patient needs.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Baystreet.ca
[email protected]
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.